ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Chemical screening of Hibiscus rosa-sinensis for their phytochemicals and their in vitro/in silico evaluation as α-amylase inhibitors.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multi-omics analysis identifies SELL and PRF1 as key immune biomarkers and therapeutic targets in tuberculosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since ancient times, flowers of Hibiscus rosa-sinensis have been a prominent ingredient of medicinal recipes. The understudied research article is a part of our experimental work to isolate bioactive molecules of flowers of Hibiscus rosa-sinensis and assess the biological potential of these molecules. Currently, we subjected the hexane and ethyl acetate fractions of crude methanolic floral extract of Hibiscus rosa-sinensis to repeated column and thin-layer chromatography. Consequently, eight known compounds were isolated and identified using spectroscopic techniques (1D and 2D NMR) as follows: taraxerol (HF1), 3,4-dimethoxycinnamic acid (HF2), β-stigmasterol glycoside (HF3), 2-hydroxy-1,7-dimethoxyanthraquinone (HF4), (E)-1-(4-hydroxyphenyl) undec-1-en-3-one (HF5), dihydroxyacetone (HF6), 1,5-dihydroxypentane-2,4-dione (HF7), and methylparaben (HF8). Further, we assessed the α-amylase inhibition capacity of isolated molecules against human pancreatic α-amylase (3BAJ) via in vitro and in silico approaches; however, the structures of isolated molecules were optimized by density functional theory (DFT). As a result of in vitro and in silico α-amylase inhibition assessment of isolated ligands, compound HF3 was explored as the most potential inhibitor of α-amylase with an IC
Indexed as
Identifiers
41343044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.